Attendee search 

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Pharmatek is a contract development & manufacturing company providing dosage form development & cGMP manufacturing of oral, injectable & topical products. Founded in 1999, our services focus on the rapid advancement of small molecule & peptide drug candidates from the bench to the clinic & include:

·         Formulation & Analytical Development

·         cGMP Manufacturing

·         Clinical Packaging, Labeling & Worldwide Distribution

Our experience includes first-in-man strategies, solutions for poorly soluble compounds, controlled release formulations & separate facilities for the handling of cytotoxic & potent compounds.  Pharmatek’s drug delivery technologies include:

·         Solid Dispersions

·         Particle Size Reduction

·         Lipid Delivery

·         Complexation

·         Lyophilization

·         Suspensions & Emulsions

Pharmatek’s 68,000 sq. ft. facility includes 9 class 100,000 cGMP manufacturing suites, formulation & analytical laboratories, & ICH stability storage.  Pharmatek has over 150 clients globally, ranging from virtual to large pharmaceutical companies. Having manufactured product for clinical trials in the North America, Europe & Asia; Pharmatek has successfully completed several large pharma quality, EH&S & QP audits.

DermSpectra has developed an innovative high resolution full body imaging system designed to aid early detection of skin cancers and diseases, and revolutionize medical documentation.  The DermSpectra Automated Total Body Digital Skin Imaging (DSI) System fills a key technology gap in medical imaging, empowers physicians with an objective tool to accurately and efficiently detect and monitor skin and body changes over time and raises the bar for patient care.

SynDevRx develops new and effective treatments for metabolic-related diseases including pre-diabetes, diabetes, obesity, dyslipidemia and fatty liver disease as well as treatments for cancer.  Our treatments are best-in-class MetAP2 inhibitors of the fumagillin drug class.  SynDevRx lead compound, SDX-7320, is a polymer conjugate of a novel fumagillol derivative which releases the pharmacologically active drug in vivo.  Our approach improves both the efficacy and safety of low molecular weight drugs while reducing systemic drug exposure compared to the small molecule drug alone.

Longevity Biotech is a privately held preclinical biotechnology company developing a new class of linear, stabilized, peptide therapeutics called Hybridtides®. 

Our objective for this meeting is to initiate fundraising (Series A) and partnership discussions to progress our preclinical neuroinflammation program into the clinic.  

To date, Longevity Biotech has demonstrated in vivo neuroprotection in a Parkinson's Disease animal model and established preliminary immunological-based biomarker end-point links to on-going clinical trials.     Longevity Biotech is encouraged to continue the development of this differentiated and potentially disease modifying therapeutic candidate to address the unmet needs across a variety of neurological disorders.  

More generally, Longevity Biotech is committed to the development of our current preclinical portfolio as well as expanding the platform breadth via licensing opportunities.  Currently, Longevity Biotech is developing GPCR based Hybridtides® for the treatment of metabolic, cardiovascular, neuroscience and oncology diseases.   In addition, preliminary data (in vitro &  in vivo) suggest the possibility of oral delivery of Hybridtide based therapeutics.

DavosPharma’s corporate offering covers all the activities required to get a drug from conception to commercialization. DavosPharma has been filling this need since 1972, serving the pharmaceutical and life science market by providing discovery chemistry & biology, pre-clinical development, and all required CMC activities including custom synthesis of organic molecules, custom dosage formulation, and custom manufacturing of cGMP intermediates, APIs, and drug product. 

AdVax is an inter/multi-disciplinary team of individuals who have developed major paradigm-shifting science, research, technology and new clinical data sets demonstrating previously unidentified bacterial infections are able to translocate to the brain and be linked to the induction of Alzheimer’s disease.

We have developed novel and proprietary real time molecular diagnostics to identify these non-culturable bacteria and then apply novel immune refocusing technologies to create both monoclonal antibodies that could be used in treatments and a first of its kind vaccine for the prevention of both cardiovascular and Alzheimer’s disease.

Our program is well on its way to identifying the major disease-inducing bacteria, which are then ready to be put into the immune refocusing technology for the derivation of human monoclonal antibodies and vaccines.

Deton is developing a novel non-invasive simple-to-use sample collection device for tuberculosis (TB) patients who are unable to provide a sample.

Proper diagnosis is essential to effectively treat the more than 9million new cases of TB every year. Typically, a sputum sample is collected to run the diagnostic test. However, in 22% of adults and in all children patients, sputum is impossible to collect. These patients have to rely on inadequate alternative collection methods that are invasive, high-cost, and resource-intensive. With our device, patients can now provide a sample even in low-resource setting and find out their TB status. Deton will enable 26M samples to be tested every year.

After promising clinical data, Deton is now raising $1.6M to build an ISO 13485 disposable product and to obtain pivotal clinical validation. Discussions with multiple potential diagnostic partners and first feedback from experts at World Health Organization show significant interest in adopting the device once effective validation has been completed. 

Headquartered in the greater Iowa City area, Corvida Medical innovates intelligent technologies that are designed to represent the next generation of safe handling of hazardous drugs and excellence in design.  We address the problems inherent in current methods and develop smarter, simpler solutions to improve safety, productivity and quality for providers and patients. Our first technology, a novel new Closed System Transfer Device – the Halo™ — will be available in 2015.